

4.0.03 DOC Cmte minutes

Neonatal Infection Guideline Update- Committee Meeting

Date: 13 July 2020

Location: Virtual committee meeting by Zoom

Minutes: Final

Committee members present:	
Waqar Shah (WS) (Chair)	Present for notes 1 – 6
Sumiah Al-Azeib (SA)	Present for notes 1 – 6
Philip Banfield (PB)	Present for notes 1 – 6
Melanie Carpenter (MC)	Present for notes 1 – 6
Mark Davies (MD)	Present for notes 1 – 6
Nicole Gannon (NG)	Present for notes 1 – 6
Paul Heath (PH)	Present for notes 1 – 6
Stephanie Jenkins (SJ)	Present for notes 1 – 6
Jane Plumb (JP)	Present for notes 1 – 6
Richard Tubman (RT)	Present for notes 1 – 6
Aung Soe (AS)	Present for notes 1 – 5

4.0.03 DOC Cmte minutes

In attendance:		
Clare Dadswell	NICE - Technical Analyst	Present for notes 1 – 6
Chris Harris	NICE - Project Manager	Present for notes 1 – 6
Kathryn Hopkins	NICE - Technical Adviser	Present for notes 1 – 6
Justine Karpusheff	NICE - Guideline Commissioning Manager	Present for notes 1 – 3
Gabriel Rogers	NICE - Technical Adviser Health Economics	Present for notes 1 – 6
Jeremy Dietz	NICE-Technical Analyst Health Economics	Present for notes 1 – 6
Sue Spiers	NICE - Associate Director	Present for notes 1 – 3
Rebecca Parsons	NICE – Programme Manager	Present for notes 1 – 5
Adam Storrow	Business Analyst - Resource Impact Assessment	Present for notes 1 – 6

Apologies:	
Jim Gray	Consultant Microbiologist

NICE observers in attendance	
Sharmila Nebhrajani (am & pm)	NICE Chairman
Simon Ellis (am & pm)	Associate Director - Commissioning
Sara Buckner (am & pm)	Technical Adviser
Debra Hunter (am & pm)	Project Manager
Lucy Beggs (am & pm)	Technical Adviser
Ian Pye (am & pm)	Project Manager
Anneka Patel (am)	Project Manager
Marie Harrisingh (am)	Senior Technical Analyst
Chris Carmona (am)	Senior Technical Analyst
Vonda Murray (am)	Project Manager
Lise Elliot (am)	Programme Manager
Becky Chadwick (am)	Guideline Coordinator
Toby Mercer (pm)	Technical Analyst

4.0.03 DOC Cmte minutes

Joseph Crutwell (pm)	Technical Analyst
Danielle Conroy (pm)	Project Manager
Anthony Gildea (pm)	Project Manager

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 7th meeting on Neonatal infections.

The Chair informed the Committee that apologies from Jim Gray had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Discussing evidence on the optimal antibiotic treatment regimen for suspected late-onset neonatal infection
- A presentation and update on Health Economic models
- An update on the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was: prevention and treatment of neonatal infection.

The DOI register was reviewed by the Chair and Committee and the Chair asked everyone to verbally declare any interests that have arisen since the last meeting. These are noted below.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Philip Barnfield	Obstetrician	Director of Obstetrica Ltd – medicolegal work	Direct financial	Declare and participate Not specific to any topic covered in the scope of the guideline – cases taken cover a broad range of neonatal care
Jane Plumb	Lay member	Co-Author; Walker K, Morris E, Plumb J, Gray J, Thornton JG, Daniel J. Universal testing for group B streptococcus during pregnancy:	Indirect financial	Declare and participate Universal screening for Group B streptococci was not considered as

4.0.03 DOC Cmte minutes

		need for a randomised trial BJOG 2020;127:693 (Publication part of previously declare GBS3 grant application)		part of the guideline update and the paper was not included in any of the evidence reviews
Jane Plumb	Lay member	Co-Author, Group B streptococcal disease in the mother and newborn—A review (European Journal of Obstetrics & Gynecology and Reproductive Biology)	Direct non-financial professional and personal	Declare and participate. Not specific to any topic covered in the scope of the guideline
Paul Heath	Paediatrician	Co-Author, PCR for the detection of pathogens in neonatal early onset sepsis.	Direct non-financial professional and personal	Declare and participate Not specific to any topic covered in the scope of the guideline.
Paul Heath	Paediatrician	Co-Author, Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis in the Hospital Setting Across Asian Countries.	Direct non-financial professional and personal	Declare and participate Relevant to review question 7.1 but did not meet the inclusion criteria for the review.
Paul Heath	Paediatrician	Co-Author, Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.	Direct non-financial professional and personal	Declare and participate. Included study for RQ7.1 Declaration does not include any personal financial gain and exclusion would remove the committee's access to relevant expertise in this area.
Paul	Paediatrician	Co-Author, An optimised dosing	Direct non-financial	Declare and

4.0.03 DOC Cmte minutes

Heath		regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial.	professional and personal	participate Relevant to review question 7.1 but did not meet the inclusion criteria for the review.
Mark Davies	Lay member	Advised two of his pervious DOI's had now ceased due to standing down: Member of the Patient Lay Committee at the Academy of Medical Royal Colleges. Member of the AoMRC Foundation Programme Committee, reviewing the Foundation Curriculum for newly-qualified doctors.	Direct financial (now ceased as at June 2020)	Declare and participate

The DOIs were considered by the Chair, no conflict of interest was identified for the meeting, and all Committee members were eligible to attend the Committee meeting and contribute to the discussions.

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting which took place on the 6 March 2020.

2. RQ7.1 What is the optimal antibiotic treatment regimen for suspected late-onset neonatal infection?

- **Presentation of clinical evidence**

The Chair introduced CD, Technical Analyst, who gave a presentation on the clinical evidence for the optimal antibiotic treatment regimen for suspected late-onset

4.0.03 DOC Cmte minutes

neonatal infection. The Chair thanked CD for their presentation.

3. RQ7.1 What is the optimal antibiotic treatment regimen for suspected late-onset neonatal infection?

- **Update on Health Economics**

The Chair introduced GR, Technical Analyst, who gave a brief update on the proposal for health economic modelling for the optimal antibiotic treatment regimen for suspected late-onset neonatal infection. The Committee discussed the proposal. The Chair thanked GR for his presentation.

3. RQ7.1 What is the optimal antibiotic treatment regimen for suspected late-onset neonatal infection?

- **Committee discussion**

The Chair facilitated a Committee discussion on the clinical evidence presented and thanked the Committee for their input and comments.

4. RQ7.2: What is the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection?

- **Presentation of clinical evidence**

The Chair introduced GR, Technical Adviser, who presented a brief introduction on the proposal for this item, followed by a brief presentation from CD, Technical Analyst on clinical evidence. The Chair thanked both GR and CD for their presentations.

5. RQ7.2 What is the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection?

- **Discussion on the approach for health economic modelling**

The Chair introduced JD, Technical Analyst, who presented the approach for economic modelling on the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection. The Chair thanked JD for his presentation.

7. AOB, summary and next steps

The Chair thanked the Committee for their time and contribution to the meeting. CH provided the committee with an overview of the next steps for this topic. The venue, date and time of the next meeting was confirmed.

4.0.03 DOC Cmte minutes

Date of next meeting: Monday 3rd August 2020

Location of next meeting: Virtual committee meeting by Zoom